Patents Assigned to ANCHORED RSK3 INHIBITORS, LLC
  • Compositions for treating heart disease by inhibiting the action of mAKAP?
    Patent number: 11229679
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: January 25, 2022
    Assignee: ANCHORED RSK3 INHIBITORS, LLC
    Inventors: Michael S. Kapiloff, Jinliang Li, Michael Kritzer
  • Treatment of myocardial infarction by inhibiting the action of mAKAP?
    Patent number: 9937228
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: April 10, 2018
    Assignee: ANCHORED RSK3 INHIBITORS, LLC
    Inventors: Michael S Kapiloff, Jinliang Li, Michael Kritzer, Catherine Passariello, Kimberly Dodge-Kafka
  • TREATMENT OF HEART DISEASE BY INHIBITION OF THE ACTION OF RIBOSOMAL S6 KINASE 3 (RSK3)
    Publication number: 20140286928
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Applicant: ANCHORED RSK3 INHIBITORS, LLC
    Inventors: Michael S. KAPILOFF, Jinliang LI, Michael KRITZER, Catherine PASSARIELLO, Kimberly DODGE-KAFKA